---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059538"
form_type: "8-K"
ticker: null
cik: "0001966494"
company_name: "CARGO Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:23:53.329774+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CARGO Therapeutics reports Q1 2024 net loss $35.8M; Phase 2 firi-cel trial on track for 1H25 interim data

## Summary
- Q1 2024 net loss of $35.8M ($0.87/share); cash, equivalents and marketable securities $375.9M providing runway into 2026.
- Phase 2 FIRCE-1: 26 sites activated, >20 patients dosed; IDMC recommended continuation without modifications; interim results expected 1H25.
- Phase 1 Stanford firi-cel data: median OS 25.7 months at DL1; ORR 68%, CR 53% across all patients (n=38) at median follow-up 31.4 months.
- Dr. Kapil Dhingra appointed to board of directors in April 2024.
- R&D expenses $30.5M (incl. $1.7M stock-based comp); G&A expenses $10.3M (incl. $2.2M stock-based comp).

## SEC filing metadata
- accession: 0000950170-24-059538
- form_type: 8-K
- cik: 0001966494
- company_name: CARGO Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1966494/000095017024059538/0000950170-24-059538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1966494/000095017024059538/crgx-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059538
- JSON: https://secwatch.observer/filing/0000950170-24-059538.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059538.txt

## Key facts
- Earnings Releases
  CARGO Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, CARGO Therapeutics, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1966494/000095017024059538/0000950170-24-059538-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.